



Universiteit
Leiden
The Netherlands

The role of apolipoprotein CI in lipid metabolism and bacterial sepsis

Berbée, J.F.P.

Citation

Berbée, J. F. P. (2007, May 24). *The role of apolipoprotein CI in lipid metabolism and bacterial sepsis*. Retrieved from <https://hdl.handle.net/1887/11973>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/11973>

Note: To cite this publication please use the final published version (if applicable).

Chapter 8

Plasma Apolipoprotein CI Protects against Mortality from Infection in Old Age

Jimmy F.P. Berbée^{1,2}, Simon P. Mooijaart³, Anton J.M. de Craen³, Louis M. Havekes^{1,2,4}, Diana van Heemst³, Patrick C.N. Rensen^{1,2}, and Rudi G.J. Westendorp³

From the ¹Department of Biomedical Research, TNO-Quality of Life, Gaubius Laboratory, P.O. Box 2215, 2301 CE Leiden, The Netherlands; Departments of ²General Internal Medicine, Endocrinology and Metabolic Diseases, ³Gerontology and Geriatrics, and ⁴Cardiology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

Submitted for publication

Abstract

Objective: Accumulating evidence indicates that apolipoproteins on the surface of lipoproteins, especially on high-density lipoprotein (HDL), are responsible for the beneficial effects of lipoproteins in the outcome of infectious disease. Recently, we showed that the HDL-constituent apolipoprotein CI (apoCI) gene-dose dependently protected mice against mortality in bacterial sepsis. In the present study we assessed whether high plasma apoCI levels protect against mortality from infection in humans.

Methods: We determined plasma levels of apoCI, lipids, and C-reactive protein, and mortality in 85-year old participants of the Leiden 85-plus Study (n=561), who were not selected on health or demographics. Participants were prospectively followed for specific causes of death for 5 years.

Results: High levels of apoCI associated with 40% reduced risk of mortality from infection (hazard ratio [HR], 0.60 [95% confidence interval ¹, 0.42-0.86]; $P=0.005$) for every increase of one standard deviation in apoCI level. A similar association was observed for high HDL-cholesterol levels (HR, 0.65 [95% CI, 0.46-0.94]; $P=0.022$). Importantly, the effect of apoCI level was independent of HDL-cholesterol, as multivariate analysis did not materially alter the association for apoCI (HR, 0.63 [95% CI, 0.44-0.90]; $P=0.013$), while for HDL-cholesterol significance was lost.

Conclusions: We conclude that high levels of apoCI associate with reduced mortality from infection in humans, in line with experimental evidence in rodents.

Introduction

Apart from regulating lipid metabolism, evidence accumulates that lipoproteins are also involved in the outcome of infectious disease²⁻⁶. In particular high high-density lipoprotein (HDL)-cholesterol levels have been associated with increased protection against infection-related mortality^{3,5,6}. Experimental studies in rodents suggest that not the lipid-content of the lipoproteins, but rather the associated surface apolipoproteins, are responsible for the protective effect against infection^{1,7-14}. Recently, we showed that apolipoprotein CI (apoCI) protected against mortality in bacterial sepsis, by using genetically engineered mice that either lack apoCI or overexpress apoCI¹. The relation between plasma levels of apoCI and infectious disease mortality in humans has not yet been studied.

ApoCI predominantly circulates as a surface component of HDL at a relatively high plasma concentration of about 6-10 mg/dL¹⁵⁻¹⁷. With 6.6 kDa it is the smallest apolipoprotein known to date. Studies *in vitro*¹⁸⁻²¹ and *in vivo*²² show that apoCI modulates the activity of plasma factors involved in HDL metabolism such as

cholesteryl ester transfer protein (CETP)^{19,22}, lecithin cholesterol acyltransferase (LCAT)²¹, and hepatic lipase (HL)^{18,20}. Studies with apoCI-deficient mice indeed showed that apoCI expression correlated positively with HDL-cholesterol levels²³. However, the fact that administration of lipid-free apoCI enhanced a beneficial proinflammatory host response towards bacterial products *in vivo*, without altering HDL-cholesterol levels¹, strongly suggests that the effect of apoCI on infection-related outcome is independent of HDL-cholesterol levels.

Here we analyzed whether in humans, high plasma apoCI levels protect against mortality from infection. To this end, we determined the plasma apoCI, lipid, and C-reactive protein (CRP) levels, and mortality from infection within the Leiden 85-plus Study, a prospective population based follow-up study of elderly aged 85 years. Within this age category, 17% of deaths occur due to infection-related causes. Our findings reveal that in the population at large, high apoCI levels indeed associate with reduced mortality from infection.

Materials and Methods

Participants – Between September 1, 1997, and September 1, 1999, a total of 705 inhabitants of the community of Leiden, the Netherlands, reached the age of 85 years. Among these 85-year-old persons, we initiated a follow-up study to investigate determinants of successful aging. There were no selection criteria on health or demographic characteristics. The response rate was 87%; a total of 599 individuals participated²⁴. There were no significant differences in various demographic characteristics between the 599 respondents and the source population. Of the 599 participants in the cohort, 38 refused to provide a blood sample, yielding a total number of 561 participants for the present study. The Medical Ethical Committee of the Leiden University Medical Center approved the study, and informed consent was obtained from all subjects.

Plasma Parameters – At baseline, subjects were visited twice at their place of residence within one month after the subjects' 85th birthday. All blood samples were collected before 11.00 a.m., although not fasting. Plasma apoCI levels were determined using a human apoCI-specific sandwich ELISA as described previously²⁵. In short, a polyclonal goat anti-human apoCI antibody (Academy Biomedical Co., Houston, TX) was coated onto Costar medium binding plates (Corning, Inc., New York, NY) and incubated with diluted human plasma (dilution 1:150,000). Subsequently, the wells were incubated with horse radish peroxidase (HRP)-conjugated polyclonal goat anti-human apoCI antibody (Academy Biomedical Co.), and finally HRP was detected by incubation with tetramethylbezidine (Organon Teknika, Boxtel, The Netherlands). Plasma from

C57Bl/6 mice spiked with human apoCI (Labconsult, Brussels, Belgium) was used as a standard.

Plasma levels of total cholesterol, HDL-cholesterol, triglycerides (TG), and CRP were analyzed on fully automated computerized analyzers (Hitachi 747 and 911; Hitachi, Ltd, Tokyo, Japan). The level of low-density lipoprotein (LDL)-cholesterol was estimated by the Friedewald equation ($\text{LDL-cholesterol [mmol/L]} = \text{total cholesterol} - \text{HDL-cholesterol} - [\text{TG}/2.2]$), whereby subjects with a TG concentration higher than 443 mg/dL (5 mmol/L) were excluded ($n = 5$).

Causes of Death – For the analyses presented in this research, all subjects were followed for mortality until April 1st, 2004. The date of death was obtained from the civic registries. Shortly after civic registries reported the death of a subject, the general practitioner or nursing home physician was interviewed to determine the cause of death by means of a standardized questionnaire. Two senior specialists of internal medicine, unaware of the outcomes of the analyses, in 2004 reviewed the causes of death and classified each death into primary causes of death according to the *International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)*. Cardiovascular mortality was classified as ICD-codes I00-I99, mortality from infection as ICD-codes A00-B99 and J10-J18, and cancer as C00-D48. All other ICD-codes were grouped as other cause mortality. Of 6 subjects the cause of death could not be established.

Statistical Analyses – Plasma levels of apoCI and total-, LDL- and HDL-cholesterol were normally distributed and are presented as means. Plasma levels of TG and CRP were not normally distributed and are presented as medians with interquartile range to assess distribution in the total population and as geometric means to compare means between groups. Individuals with undetectable CRP levels were attributed half of the minimal detection limit (0.25 mg/L) to allow log-transformation. Differences in levels of these lipids were calculated using sex-adjusted linear regression. Mortality risks were estimated using Cox Proportional Hazards models, which were all adjusted for gender. All calculations were performed using SPSS 12.0.1, Kaplan Meier curves were generated using STATA 9 SE.

Results

Baseline Characteristics and Lipid Correlations – The baseline characteristics of the study population are listed in Table 1. The mean plasma apoCI concentration was 6.68 ± 2.07 mg/dL, comparable with concentrations reported in other populations¹⁵⁻¹⁷.

Correlation of plasma apoCI levels with all classical lipid parameters revealed a strong and positive association between plasma apoCI levels and levels of total-, LDL- and HDL-cholesterol, and TG (Table 2; all $P < 0.001$). In addition, we found a negative association between plasma apoCI levels and plasma CRP levels (Table 2; $P < 0.01$)

Mortality – Since our previous experimental studies in mice showed that high plasma apoCI levels are associated with reduced mortality from infection¹, we calculated the risk of mortality from infection dependent on the plasma levels of apoCI. Of the 561 participants, 48 subjects (17%) died due to infection-related cause. As shown in Figure 1, subjects with high plasma levels of apoCI (above the median) had a significant reduced cumulative risk of mortality from infection as compared with subjects with low plasma apoCI levels (below the median). In a sex-adjusted Cox proportional hazards model the risk of mortality decreased by a factor of 0.60 (95% confidence interval 0.42-0.86; $P = 0.005$) for every increase of one standard deviation in apoCI level.

To determine whether high levels of apoCI specifically associated with reduced mortality from infection, and were not a general reflection of good health, we calculated risk of mortality from different causes dependent on plasma apoCI levels (Table 3). The risk of all cause mortality decreased by a factor of 0.79 (95% confidence interval 0.69-0.91; $P = 0.001$) for every increase of one standard deviation in plasma apoCI level. In contrast to the strong association of plasma apoCI levels with mortality from infection, the association with cardiovascular disease mortality was weaker (0.79; 95% confidence interval 0.64-0.99; $P = 0.036$).

Table 1: Baseline characteristics of study participants.

Total number (n)	561
Sex	
Female (number, %)	374 (67%)
Male (number, %)	187 (33%)
Plasma apolipoprotein levels in mg/dL	
ApoCI, mean (SD)	6.68 (2.07)
Plasma lipid levels in mmol/L	
Total cholesterol, mean (SD)	5.71 (1.13)
LDL-cholesterol, mean (SD)	3.68 (0.97)
HDL-cholesterol, mean (SD)	1.31 (0.40)
Triglycerides (IQR)	1.34 (1.00-1.95)
Plasma cytokine levels	
CRP, median (IQR) in mg/L	4.0 (1.0-8.0)

Abbreviations: SD, Standard Deviation; IQR, Inter Quartile Range; CRP, C-reactive protein.

No significant associations between plasma apoC1 levels and mortality from cancer (0.88; 95% confidence interval 0.62-1.27) or from 'other causes' (0.88; 95% confidence interval 0.67-1.16) were found.

Previously, we found that in elderly only high HDL-cholesterol levels are associated with decreased mortality from infection, and not LDL-cholesterol or TG levels ⁵. Although relatively weak, we show here that plasma apoC1 levels were positively correlated with HDL-cholesterol levels (Table 2). Therefore, we investigated whether the reduced risk of mortality from infection with high apoC1 levels was dependent on the association of apoC1 with HDL-cholesterol. To this end, we repeated the mortality analysis for HDL-cholesterol. For every increase of one standard deviation in plasma HDL-cholesterol level the risk of mortality from infection decreased by a factor of 0.65 (95% confidence interval 0.46-0.94; $P=0.022$). When apoC1 and HDL-cholesterol were simultaneously entered in the model, the protective effect of apoC1 on mortality from infection remained similar (0.63; 95% confidence interval 0.44-0.90; $P=0.013$), while for HDL-cholesterol the protective effect slightly decreased and significance was lost (0.72; confidence

Table 2. Plasma levels of lipid parameters and CRP according to quartiles of plasma apoC1 levels.

Lipid level, mean (95% CI)	Quartiles of plasma apoC1 levels				<i>P</i> for trend*
	very low (n=140)	low (n=141)	high (n=138)	very high (n=142)	
ApoC1 (mg/dL)	4.30 (4.17-4.45)	5.86 (5.72-6.00)	7.16 (7.02-7.31)	9.38 (9.42-9.52)	n.d.
Total cholesterol (mmol/L)	5.09 (4.92-5.26)	5.54 (5.37-5.70)	5.88 (5.72-6.05)	6.34 (6.17-6.50)	<0.001
LDL-cholesterol (mmol/L)	3.35 (3.20-3.51)	3.55 (3.40-3.70)	3.78 (3.63-3.94)	4.03 (3.87-4.19)	<0.001
HDL-cholesterol (mmol/L)	1.14 (1.07-1.20)	1.31 (1.25-1.37)	1.41 (1.35-1.47)	1.40 (1.34-1.47)	<0.001
Triglycerides (mmol/L)†	1.22 (1.13-1.32)	1.35 (1.26-1.45)	1.40 (1.30-1.51)	1.70 (1.58-1.83)	<0.001
CRP (mg/L)†	4.39 (3.45-5.64)	2.36 (1.86-3.00)	2.64 (2.08-3.39)	2.32 (1.82-2.94)	0.002

Mean levels (and 95% confidence interval of the mean (95% CI)) were sex-adjusted. All subjects were aged 85 years.

Abbreviations: n.d., not determined; CRP, C-reactive protein.

* *P* for trend calculated using sex-adjusted linear regression

† geometrical means

interval 0.49-1.04; $P=0.074$). Moreover, there was no significant interaction of the risk of mortality from infection associated with high levels of apoC1 and the risk of mortality from infection associated with high levels of HDL-cholesterol (not shown; $P=0.681$).




Figure 1. Cumulative mortality from infection dependent on plasma apoC1 levels. Kaplan-Meier curves for mortality from infection for subjects with high (above median) and low (below median) plasma apoC1 level. The P -value indicates statistical significant in a sex-adjusted Cox proportional hazards model.

Discussion

The results of the present prospective population-based study show that in old age high plasma apoC1 levels are strongly associated with lower risk of mortality from infection. The protective effect of apoC1 was specific for mortality from infection and independent of HDL-cholesterol levels. Our previous experimental studies in which we showed that apoC1 was protective in a murine bacterial sepsis model¹ can thus be extrapolated to humans.

Our results show that, within the Leiden 85-plus Study, subjects with high plasma apoC1 levels at baseline are less prone to mortality from infection during a five-year follow-up period. To our knowledge there is only one report published on the relation between apoC1 and infection in humans, which showed that HDL was virtually depleted from apoC1 during human sepsis²⁶, supportive for a role of apoC1 in human infection. We also found total plasma levels of apoC1 to be decreased in septic patients, and that this decrease was selective as compared with levels of lipoprotein lipids (Berbée JFP, Havekes LM, and Rensen PCN, unpublished data).

From our previous study¹, we have concluded that high plasma levels of apoC1 effectuate a more efficient killing of invading microorganisms, by virtue

Table 3. Risk of all cause mortality and mortality from specific causes dependent on plasma apoCI levels.

Cause (cases)	Hazard ratio per SD increase in apoCI level	P-value *
All causes (n=282)	0.79 (0.69-0.91)	0.001
Infection (n=48)	0.60 (0.42-0.99)	0.005
Cardiovascular (n=117)	0.79 (0.64-0.99)	0.036
Cancer (n=45)	0.88 (0.62-1.27)	0.427
Other (n=66)	0.88 (0.67-1.16)	0.376

Hazard ratios for all cause mortality and mortality from specific causes represent the relative risk of mortality associated with 1 standard deviation (SD) increase of plasma apoCI level, calculated using a sex-adjusted Cox proportional hazards model.

* P-values indicate statistical significance of difference of the reported hazard ratio from unity.

of an increased sensitivity to respond to microorganisms and a concomitant increased proinflammatory host response. This results in a low bacterial load, and consequently a reduced mortality risk. This host defense mechanism has been outstandingly described by Netea *et al.*²⁷, who stated that a proinflammatory cytokine response is crucial to surmount early phase bacterial infection, whereas in a late phase a high proinflammatory response is often harmful and may lead to tissue damage and organ failure. The mechanism behind the decrease in apoCI levels during sepsis is not yet understood. It may well be that the decrease in apoCI levels is a natural response of the host in an attempt to protect itself against an overwhelming cytokine response in a latter phase of infection, a speculation which is subject of ongoing investigation.

Based on our current findings, the association of plasma apoCI levels with reduced mortality appears to be specific for mortality from infection, since apoCI levels are not significantly associated with cancer mortality and 'other cause' mortality, and we only found a weak association between apoCI levels and cardiovascular disease mortality. This weak association between reduced cardiovascular disease mortality and high apoCI levels is in line with the observed negative association between plasma CRP and apoCI levels in these subjects. High circulating levels of CRP are a marker of chronic inflammation and cardiovascular disease^{28,29}. Another explanation for the observation that in our population high levels of apoCI are associated with decreased cardiovascular mortality is that plasma apoCI levels positively associate with HDL-cholesterol levels as we show in this study. The role of HDL in preventing cardiovascular disease has indisputably been established³⁰⁻³². ApoCI is able to directly increase HDL levels by modulation of several enzymes involved in HDL metabolism.

ApoCI is the main endogenous inhibitor of CETP^{19,22}, an inhibitor of HL^{18,20}, and an activator of LCAT²¹. These are all mechanisms shown to increase HDL-cholesterol, indicating that high plasma apoCI levels could improve cardiovascular outcome via increasing HDL-cholesterol levels.

The observed association of high levels of apoCI with decreased mortality from infection was independent of HDL-cholesterol levels. A possible explanation for this finding is that a dual protective mechanism is exerted by apoCI and HDL. ApoCI is involved in a more effective elimination of the pathogens, as discussed above, while HDL may improve neutralization of microbial products such as LPS. Another possibility is that this knowledge 'explains' why high cholesterol levels, and in particular high HDL-cholesterol levels, have previously been associated with a beneficial outcome of infection-related mortality in humans, a finding that is not yet been properly understood²⁻⁶. Accumulating evidence from primarily experimental studies shows that not the lipids^{1,11,12}, but rather the apolipoproteins located on the surface of lipoproteins determine the effect of the lipoproteins on the host response to infectious agents^{9,11,33} and subsequent survival^{8,10,11,13,14}. Van der Poll *et al.*¹² showed that continuous infusion of Intralipid, a protein-free lipid emulsion, in humans did not affect inflammatory responses to LPS, the toxic component of Gram-negative bacteria. Likewise, LDL-receptor (LDLr) and LDLr-related protein double-deficient mice showed no altered inflammatory response after LPS-stimulation as compared to wild-type mice¹, despite the severe hyperlipidemic phenotype in these mice³⁴. These findings indicate that lipids per se do not alter the infection-related host responses.

Our previous experiments in mice mainly focused on the role of apoCI in Gram-negative bacterial sepsis¹, since we found that the C-terminus of apoCI contains a highly conserved lysine-rich motif (i.e. *KVKEKLK*) involved in the avid binding of apoCI to LPS. We demonstrated that apoCI avidly bound LPS and stimulated the inflammatory response to LPS, thereby improving the antibacterial attack. However in the population at large, in addition to Gram-negative bacteria as one of the major contributors, also Gram-positive bacteria and other infectious microorganisms such as fungi are responsible for infectious disease mortality³⁵. Since we show here that high plasma levels of apoCI protect against mortality from infection in the population at large, one may speculate that apoCI has a role in the host defense against microorganisms beyond that of Gram-negative bacteria only.

A limitation of our study is that this finding cannot be directly extrapolated beyond this age group. The risk of high plasma apoCI levels for mortality from infection in middle age has yet to be determined. On the basis of official data from the Dutch Bureau of Statistics, 15% of men and 36% of women born between 1912 and 1914 actually survived until the age of 85 years. On the one hand, this

may be regarded as a minority of the total birth cohort and does not allow for extrapolation of our findings to other age groups. On the other hand, apparently a substantial portion of the total population reaches this age-category and an even larger portion will reach it in the near future. A strength of our study is the specificity and sensitivity of the analyses due to the high incidence of fatal events during follow-up. Moreover, the data come from a population based study without inclusion criteria on health and demographic characteristics.

We conclude that high plasma apoCI levels protect against mortality from infection independent of HDL-cholesterol. Our results support our previously proposed mechanism, in which apoCI functions as part of the innate host defense mechanism against invading microorganisms.

Acknowledgements

This study was supported in part by the Netherlands Organization for Scientific Research (NWO RIDE 014-90-001 to L.M.H., NWO VIDI 917-36-351 to P.C.N.R.), by the Leiden University Medical Center (Gisela Thier Fellowship to P.C.N.R.), and by the Dutch Ministry of Economic Affairs (IOP grant IGE01014 to R.G.J.W.). Funders did not have any role in the design, analysis, interpretation and report of the present study. J.F.P. Berbee and S.P. Mooijaart had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, Van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. *FASEB J* 2006;20:2162-2164.
2. Canturk NZ, Canturk Z, Okay E, Yirmibesoglu O, Eraldemir B. Risk of nosocomial infections and effects of total cholesterol, HDL cholesterol in surgical patients. *Clin Nutr* 2002;21:431-436.
3. Delgado-Rodriguez M, Medina-Cuadros M, Martinez-Gallego G, Sillero-Arenas M. Total cholesterol, HDL-cholesterol, and risk of nosocomial infection: a prospective study in surgical patients. *Infect Control Hosp Epidemiol* 1997;18:9-18.
4. van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, Van Strijp JA, Verhoef J, Van Kessel KP. The role of high density lipoprotein in sepsis. *Neth J Med* 2001;59:102-110.
5. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. *Arch Intern Med* 2003;163:1549-1554.
6. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. *Shock* 2004;21:210-221.
7. Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. *J Endotoxin Res* 2005;11:97-103.
8. de Bont N, Netea MG, Demacker PN, Verschueren I, Kullberg BJ, van Dijk KW, van der Meer JW, Stalenhoef AF. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and *Klebsiella pneumoniae* infection. *J Lipid Res* 1999;40:680-685.
9. Feingold KR, Grunfeld C. Lipoproteins: are they important components of host defense? *Hepatology* 1997;26:1685-1686.
10. Ma J, Liao XL, Lou B, Wu MP. Role of apolipoprotein A-I in protecting against endotoxin toxicity.

- Acta Biochim Biophys Sin (Shanghai)* 2004;36:419-424.
11. Rensen PC, Oosten M, Bilt E, Van Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats *In vivo*. *J Clin Invest* 1997;99:2438-2445.
12. Van der Poll T, Braxton CC, Coyle SM, Boermeester MA, Wang JC, Jansen PM, Montegut WJ, Calvano SE, Hack CE, Lowry SF. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. *Infect Immun* 1995;63:3396-3400.
13. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ, Vogel T, Panet A, Van Berkel TJ, Kuiper J. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. *J Biol Chem* 2001;276:8820-8824.
14. Vowinkel T, Mori M, Kriegelstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, Kalogeris TJ. Apolipoprotein A-IV inhibits experimental colitis. *J Clin Invest* 2004;114:260-269.
15. Cohn JS, Tremblay M, Boulet L, Jacques H, Davignon J, Roy M, Bernier L. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. *Atherosclerosis* 2003;169:63-70.
16. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electroimmunoassays. *Clin Chem* 1981;27:543-548.
17. Shachter NS, Rabinowitz D, Stohl S, Conde-Knape K, Cohn JS, Deckelbaum RJ, Berglund L, Shea S. The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. *Atherosclerosis* 2005;179:387-393.
18. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. *J Lipid Res* 2002;43:2136-2145.
19. Gautier T, Masson D, de Barros JP, Athias A, Gamber P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. *J Biol Chem* 2000;275:37504-37509.
20. Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. *FEBS Lett* 1976;65:354-357.
21. Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM, Smith LC. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. *Biochemistry* 1975;14:3057-3064.
22. Gautier T, Masson D, Jong MC, Duverneuil L, Le Guern N, Deckert V, Pais de Barros JP, Dumont L, Bataille A, Zak Z, Jiang XC, Tall AR, Havekes LM, Lagrost L. Apolipoprotein C-I deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoC1-knocked out mice. *J Biol Chem* 2002;277:31354-31363.
23. Gautier T, Tietge UJ, Boverhof R, Pertion FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F. Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. *J Lipid Res* 2007;48:30-40.
24. Bootsma-Van der Wiel AB, van Exel E, de Craen AJ, Gussekloo J, Lagaay AM, Knook DL, Westendorp RG. A high response is not essential to prevent selection bias: results from the Leiden 85-plus study. *J Clin Epidemiol* 2002;55:1119-1125.
25. Berbee JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. *J Lipid Res* 2005;46:297-306.
26. Barlage S, Frohlich D, Bottcher A, Jauhainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke R, Lackner KJ, Ehnolm C, Schmitz G. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. *J Lipid Res* 2001;42:281-290.
27. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? *Trends Immunol* 2003;24:254-258.
28. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;352:20-28.
29. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. *Thromb Haemost* 2006;95:511-518.
30. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final

- report. *Circulation* 2002;106:3143-3421.
31. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation* 1989;79:8-15.
 32. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). *Circulation* 2005;112:3058-3065.
 33. van den Elzen EP, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB. Apolipoprotein-mediated pathways of lipid antigen presentation. *Nature* 2005;437:906-910.
 34. Espirito Santo SM, Rensen PC, Goudriaan JR, Bensadoun A, Bovenschen N, Voshol PJ, Havekes LM, van Vlijmen BJ. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. *J Lipid Res* 2005;46:1097-1102.
 35. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003;348:1546-1554.